NCT03265808View on ClinicalTrials.gov

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 18, 2018

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Major Depressive DisorderAlcohol Use Disorder
Interventions
DRUG

allogeneic human mesenchymal stem cells (allo-hMSCs)

Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.

DRUG

Placebo

Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.

Trial Locations (1)

78550

University of Texas Rio Grande Valley School of Medicine, Harlingen

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Ihsan M Salloum, MD, MPH

OTHER

NCT03265808 - Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression. | Biotech Hunter | Biotech Hunter